Quassinoids from the root of Eurycoma longifolia and their antiproliferative activity on human cancer cell lines

Articles

Abstract
Pharmacognosy Magazine,2017,13,51,459-462.
Published:July 2017
Type:Original Article
Authors:
Author(s) affiliations:

Nguyen Huu Tung1, Takuhiro Uto2, Nguyen Thanh Hai3, Gang Li2, Yukihiro Shoyama2
1Department of Pharmacognosy, Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo, Nagasaki 859-3298, Japan; Department of Pharmacy, School of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam
2Department of Pharmacognosy, Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo, Nagasaki 859-3298, Japan
3Department of Pharmacy, School of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam

Abstract:

Background: The roots of Eurycoma longifolia Jack have traditionally been used as an aphrodisiac tonic besides the other remedies for boils, fever, bleeding gums, and wound ulcer. Recently, the antiproliferative activity of E. longifolia has been reported and remained attractive to natural chemists. Objective: The objective of this study was to study on antiproliferative compounds from the root of E. longifoliaMaterials and Methods: Column chromatography was used to separate individual compounds, spectroscopic data including nuclear magnetic resonances and mass spectrometry were analyzed to determine the chemical structure of the isolates and for biological testing, antiproliferative activity of compounds was tested on seven human cancer cell lines (KATO III, HCT-15, Colo205, HepG2, PC-3, Jurkat, HL-60) by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method. Results: Nine quassinoids including a new C19longilactone-type quassinoid glycoside were characterized from the roots of the title plant. Among them, the major quassinoid eurycomanone exhibited selectively potential antiproliferative activities on the leukemia cell lines (HL-60 and Jurkat) and had very low toxic effects on normal skin fibroblast cell line (NB1RGB). Conclusion: The current study reveals one new quassinoid glycoside and the potential active component (eurycomanone) from E. longifolia for the leukemia treatment.

PDF
Keywords